Circulation, Vol 67, 1290-1295, Copyright © 1983 by American Heart Association
H Hammerman, RA Kloner, FJ Schoen, EJ Brown Jr, S Hale and E Braunwald
We investigated the effect of indomethacin, a widely used nonsteroidal
antiinflammatory drug, on the healing of myocardial infarction (MI).
Experimental MI was produced in anesthetized, open-chest dogs by occluding
the left anterior descending coronary artery. Ten dogs received
indomethacin, 10 mg/kg i.v., and 11 received saline, 15 minutes and 3 hours
after occlusion. After 6 weeks, the dogs were killed and their hearts were
subjected to morphologic and biochemical analysis. The average thickness of
the transmural scar and the noninfarcted left ventricular wall was measured
at multiple sites in formalin-fixed left ventricular slices and the ratio
of the thickness of the transmural scar to the noninfarcted wall
determined. The average thickness of the noninfarcted wall was 8.80 +/-
0.19 mm (mean +/- SEM) in the control group and 8.44 +/- 0.26 mm in the
indomethacin group (NS). The scar thickness was 7.24 +/- 0.64 mm in the
control group and 3.56 +/- 0.40 mm in the indomethacin group (p less than
0.001). The ratio of scar to noninfarcted wall thickness was 0.83 +/- 0.07
in the control group and 0.43 +/- 0.04 in the indomethacin group (p less
than 0.001). Scars in treated dogs did not differ from controls either by
light microscopic histologic analysis or by analysis of hydroxyproline
content per unit weight. We conclude that indomethacin results in marked
scar thinning when given early after experimental MI.
ARTICLES
Indomethacin-induced scar thinning after experimental myocardial infarction
This article has been cited by other articles:
![]() |
U. Landmesser, K. C. Wollert, and H. Drexler Potential novel pharmacological therapies for myocardial remodelling Cardiovasc Res, February 15, 2009; 81(3): 519 - 527. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. I. Jugdutt Cyclooxygenase Inhibition and Adverse Remodeling During Healing After Myocardial Infarction Circulation, January 23, 2007; 115(3): 288 - 291. [Full Text] [PDF] |
||||
![]() |
L. Timmers, J. P.G. Sluijter, C. W.J. Verlaan, P. Steendijk, M. J. Cramer, M. Emons, C. Strijder, P. F. Grundeman, S. K. Sze, L. Hua, et al. Cyclooxygenase-2 Inhibition Increases Mortality, Enhances Left Ventricular Remodeling, and Impairs Systolic Function After Myocardial Infarction in the Pig Circulation, January 23, 2007; 115(3): 326 - 332. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Lange and L. D. Hillis Acute Pericarditis N. Engl. J. Med., November 18, 2004; 351(21): 2195 - 2202. [Full Text] [PDF] |
||||
![]() |
K. Ohta, T. Nakajima, A. Y. L. Cheah, S. H. E. Zaidi, N. Kaviani, F. Dawood, X.-M. You, P. Liu, M. Husain, and M. Rabinovitch Elafin-overexpressing mice have improved cardiac function after myocardial infarction Am J Physiol Heart Circ Physiol, July 1, 2004; 287(1): H286 - H292. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. W. Mahaffey, C. B. Granger, J. C. Nicolau, W. Ruzyllo, W. D. Weaver, P. Theroux, J. S. Hochman, T. G. Filloon, C. F. Mojcik, T. G. Todaro, et al. Effect of Pexelizumab, an Anti-C5 Complement Antibody, as Adjunctive Therapy to Fibrinolysis in Acute Myocardial Infarction: The COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) Trial Circulation, September 9, 2003; 108(10): 1176 - 1183. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Khalil, E. N. Heller, F. Boctor, E. J. Brown Jr, and I. A. Alhaddad Ventricular Free Wall Rupture in Acute Myocardial Infarction Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2001; 6(3): 231 - 236. [Abstract] [PDF] |
||||
![]() |
R. Van Kerckhoven, E. A.J Kalkman, P. R Saxena, and R. G Schoemaker Altered cardiac collagen and associated changes in diastolic function of infarcted rat hearts Cardiovasc Res, May 1, 2000; 46(2): 316 - 323. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G Schoemaker, P. R Saxena, and E. A.J Kalkman Low-dose aspirin improves in vivo hemodynamics in conscious, chronically infarcted rats Cardiovasc Res, January 1, 1998; 37(1): 108 - 114. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. H. Birdsall, D. M. Green, J. Trial, K. A. Youker, A. R. Burns, C. R. MacKay, G. J. LaRosa, H. K. Hawkins, C. W. Smith, L. H. Michael, et al. Complement C5a, TGF-ß1, and MCP-1, in Sequence, Induce Migration of Monocytes Into Ischemic Canine Myocardium Within the First One to Five Hours After Reperfusion Circulation, February 4, 1997; 95(3): 684 - 692. [Abstract] [Full Text] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1983 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |